18th ESO-ESMO Masterclass in Clinical Oncology
30 ESCO credits
23.03.2019 - 28.03.2019
Nauen OT Gross Berhnitz (Berlin area)
MASTERCLASS
Description
Chairs: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Advisors: F. Lordick, DE - R. Popescu, CH
AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam.
The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, colorectal, lung, genito-urinary, gynaecological, head and neck cancers.
Spotlight sessions will facilitate compact update on mentorship, cancer of unknown primary, immuno-oncology, low and high grade lymphomas, neuro-endocrine tumours, case based management of sarcomas, molecular tumour boards, melanoma, supportive and palliative care, mind body medicine, burn-out syndrome, basic public speaking and developments in liquid biopsy in oncology.
TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairmen and the faculty. Informal discussion will be facilitated during the lunches and the aperitifs with the experts.
All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and fluency in English is necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the communication skills sessions will be attended jointly.
THE MASTERCLASS IS
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.
Faculty
FACULTY (as of September 2018)
M. Aapro, Clinique de Genolier, Oncology Dpt., Genolier, CH
A. Arber, University of Surrey, Faculty of Health and Medical Sciences, Guildford, UK
S. Banerjee, The Royal Marsden NHS Trust Foundation, Dept. of Gynaeclogy, London, UK
P. Casali, National Cancer Institute, Medical Oncology Dpt., Milan, IT
G. Curigliano, European Institute of Oncology, Department of Medicine, Division of Experimental Therapeutics, Milano, IT
U. Dafni, Centre Hospitalier Universitaire Vaudois, Dept. of Oncology, Lausanne, CH
J. De Munter, University Hospital Ghent, Oncology Dpt., Ghent, BE
M. De Santis, Charité University Hospital, Urology Clinic, Berlin, DE
A. Dietz, University Hospital Leipzig, ENT Department, Leipzig, DE
M. Dreyling, Munich University Hospital, Medical Clinic III, Munich, DE
A. Eniu, Cancer Institute "Ion Chiricuta", Dept. of Breast Cancer, Cluj-Napoca, RO
K. Fizazi, Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, FR
W. Gatzemeier, Humanitas Cancer Center, Breast Unit, Rozzano, IT
D. Hart, Cameron Communications, London, UK
S. Hillinger, University Hospital Zurich, Thoracic Surgery Dpt., Zurich, CH
A. Hoy, Consultant in Palliative Medicine, Epsom, UK
F. Lordick, University Hospital Leipzig, University Cancer Center Leipzig, Leipzig, DE
F. Mc Donald, The Royal Marsden NHS Foundation Trust, Dept. of Radiotherapy, London, UK
O. Michielin, Lausanne University Hospital - CHUV, Dept. of Medical Oncology, Lausanne, CH
R. Orecchia, European Institute of Oncology, Div. of Radiotherapy, Milan, IT
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Breast Unit, Bellizona, CH
N. Pavlidis, University Hospital of Ioannina, Div. of Medical Oncology, Ioannina, GR
R. Popescu, Hirslanden Klinik Aarau, Tumor Center - Dept. of Medical Oncology, Aarau, CH
G. Pruneri, University of Milan – European Institute of Oncology, Dept. of Pathology - Biobank for Translational Medicine Dpt., Milano, IT
M. Schumacher, Hirslanden Klinik Aarau, Dept. of Urology, Aarau, CH
J. Sehouli, Charité Medical University, Gynaecological Clinic, Berlin, DE
C. Sessa, Oncology Institute of Southern Switzerland, Div. of Medical Oncology, Bellinzona, CH
R. Stahel, University Hospital Zurich, Cancer Center Zurich, Zurich, CH
C. Toumpanakis, Royal Free Hospital, Centre for Gastroenterology, London, UK
E. Van Cutsem, University Hospital Leuven, Digestive Oncology Dpt., Leuven, BE
R. Verity, King's College London, Florence Nightingale Faculty of Nursing and Midwifery, London, UK
J.B. Vermorken, Antwerp University Hospital, Dept. of Medical Oncology, Edegem, BE
P. Vlummens, University Hospital Ghent, Oncology Dpt., Ghent, BE
J. Weitz, University Hospital Carl Gustav Carus, Dept. of Visceral, Thoracic and Vascular Surgery, Dresden, DE
M. Weller, University Hospital Zurich, Dept. of Neurology, Zurich, CH
H. Wikman, university Hospital Hamburg-Eppendorf, Center for Experimental Medicine, Hamburg, DE
C. Witt, University Hospital Zurich and University of Zurich, Inst. Complementary and Integrative Medicine, Zurich, CH
General information
ORGANISING SECRETARIAT
Francesca Marangoni
Ph: +39 02 85464525
Email: fmarangoni@eso.net
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Fax: +39 02 85464545
Applications
Corinne Hall
Ph: +39 02 85464522
Email: chall@eso.net
ACCREDITATION
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising secretariat.
The Masterclass has also been accredited with 25 Cat.1 ESMO MORA points.
ACKNOWLEDGEMENTS
The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are (as of June 2018):
• Platinum member: Astrazeneca, BMS
• Gold members: Eli Lilly, Helsinn, Pfizer
• Silver members: Amgen, Celgene Corporation, Genomic Health, Novartis Oncology, Sandoz Biopharmaceutical, Takeda Pharmaceuticals International AG
SOCIAL MEDIA
Follow updates, send questions and join in the discussions using #19MCO on Twitter and Facebook.
IMPORTANT DEADLINES |
||
Application deadline: | 01 December 2018 | |
---|---|---|
Save event date: | 23 March 2019 |
Application
PARTICIPANT'S PROFILE
• Age between 30 and 40 years
• At least 2-3 years’ experience in medical oncology or clinical oncology
• Involvement in scientific activities
• Fluency in English
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and accommodation
THE APPLICATION DEADLINE HAS PASSED (1 DECEMBER 2018)
Programme
23 March
Participants' arrival, airport transfers, registration | ||
13:00 | Lunch |
|
14:00 | Focus on ESO, ESMO and EONS N. Pavlidis, GR - R. Stahel, CH - R. Verity, UK |
|
PARALLEL SESSIONS | ||
14:30 | Communication Skills Workshop - 2 Groups A. Arber, UK - A. Hoy, UK |
|
14:30 | Warm up + Case presentations by participants - 2 Groups R. Popescu, CH - R.A. Stahel, CH |
|
16:30 |
Coffee break |
|
17:00 | Communication Skills Workshop - 2 Groups A. Arber, UK - A. Hoy, UK |
|
17:00 |
Warm up + Case presentations by participants - 2 Groups F. Lordick, DE - N. Pavlidis, GR |
|
20:00 | Dinner |
24 March
8:15 | Clinical session Lung cancer Chair: R.A. Stahel, CH |
|
Surgery S. Hillinger, CH Radiotherapy F. Mc Donald, UK Chemotherapy and targeted treatment R.A. Stahel, CH Immunotherapy of thoracic malignancies R.A. Stahel, CH Small cell lung cancer F. Mc Donald, UK General discussion |
||
11:00 | Coffee break | |
11:30 | Tumour board Lung cancer R.A. Stahel, CH - F. Mc Donald, UK - S. Hillinger, CH |
|
12:30 | Spotlight session Mentorship R.A. Stahel, CH |
|
13:00 | Lunch with the expert |
|
14:00 | Spotlight session Cancer of unknown primary N. Pavlidis, GR |
|
14:30 | Spotlight session Case based management of issues in immuno-oncology R.A. Stahel, CH |
|
15:10 | Spotlight session Low and high grade lymphomas: recent therapeutic advances M. Dreyling, DE |
|
15:50 | Case presentations by participants (4 groups) F. Lordick, DE - N. Pavlidis, GR - R. Popescu, CH - R.A. Stahel, CH |
|
18:30 | Networking Aperitif |
|
19:30 | Dinner |
25 March
8:15 |
Clinical session Gastro-intestinal tumours Chair: E. van Cutsem, BE |
|
Systemic treatment in early and advanced gastric cancer F. Lordick, DE Pancreatic cancer R. Popescu, CH Management of rectal cancer (surgery and radiotherapy) J. Weitz, DE Systemic treatment in adjuvant setting in colon cancer E. van Cutsem, BE Systemic treatment in advanced colon cancer E. van Cutsem, BE |
||
10:45 | Coffee break |
|
Contribution of surgery on stage IV colon cancer J. Weitz, DE |
||
General discussion | ||
12:00 | Tumour board Gastro-intestinal tumours F. Lordick, DE - R. Popescu, CH - E. van Cutsem, BE |
|
13:00 | Lunch with the expert |
|
14:00 | Spotlight session Burn-out syndrome S. Banerjee, UK |
|
14:30 | Spotlight session Case-based management of supportive and palliative care M. Aapro, CH |
|
15:00 | Spotlight session Molecular tumour boards O. Michielin, CH |
|
15:40 | Spotlight session Melanoma O. Michielin, CH |
|
18:30 | Networking Aperitif |
|
19:30 | |
Dinner |
26 March
8:15 | Clinical session Breast cancer (early and advanced) Chair: G. Curigliano, IT |
|
Pathology G. Pruneri, IT Surgery W. Gatzemeier, IT Radiotherapy R. Orecchia, IT Treatment of Luminal O. Pagani, CH Treatment of HER-2+ A. Eniu, RO |
||
10:40 | Coffee break |
|
Treatment of triple negative G. Curigliano, IT General discussion |
||
12:00 | Tumour board Breast cancer G. Curigliano, IT - O. Pagani, CH - W. Gatzemeier, IT - A. Eniu, RO - G. Pruneri, IT - R. Orecchia, IT |
|
13:00 | Lunch with the expert |
|
14:00 | Spotlight session Case based management of soft tissue sarcomas P. Casali, IT |
|
14:45 | Spotlight session Essentials in biostatistics U. Dafni, CH |
|
15:15 | Spotlight session Mind body medicine C. Witt, CH |
|
15:45 | Clinical case presentation by a doctor and a nurse P. Vlummens, BE - J. De Munter, BE |
|
16:20 | Discussion |
|
16:30 | Spotlight session Neuro-endocrine tumours C. Toumpanakis, UK |
|
18:30 | Networking Aperitif |
|
19:30 | Dinner + special evening |
27 March
8:15 | Clinical session Genito-urinary cancers Chair: K. Fizazi, FR |
|
Localized prostate cancer M. Schumacher, CH Treatment of metastatic castration sensitive prostate cancer K. Fizazi, FR Castration-resistant prostate cancer K. Fizazi, FR Metastatic renal cancer: evidence-based treatment M. De Santis, DE Treatment of bladder cancer M. De Santis, DE General discussion |
||
10:45 | Coffee break | |
11:15 | Tumour board Genito-urinary cancers K. Fizazi, FR - R. Orecchia, IT - M. Schumacher, CH |
|
12:15 | Spotlight session Basic public speaking D. Hart, UK |
|
13:00 | Lunch with the expert |
|
14:00 | Clinical session Head and neck cancer Chair: Jan B. Vermorken, NL |
|
Prognostic factors and surgical approach A. Dietz, DE Radiotherapy R. Orecchia, IT Systemic therapy and radio- chemo-therapy J.B. Vermorken, NL General discussion |
||
16:00 | Tumour board Head & Neck cancer A. Dietz, DE - R. Orecchia, IT - J.B. Vermorken, NL |
|
16:30 | Spotlight session Brain tumours M. Weller, CH |
|
18:30 | Networking Aperitif |
|
19:30 | Dinner |
28 March
8:15 | Clinical session Gynaecological cancers Chair: J.B. Vermorken, BE |
|
Surgery J. Sehouli, DE Ovarian cancer J.B. Vermorken, BE Cervical and endometrial cancers C. Sessa, CH General discussion |
||
10:30 | Coffee break |
|
11:00 | Tumour board Gynaecological cancers (2 cases) J.B. Vermorken, DE - C. Sessa, CH |
|
11:30 | Learning Assessment Test | |
12:30 | Keynote session Developments in liquid biopsy in oncology H. Wikman, DE |
|
13:00 | Closing remarks |